Clinical and demographical features, function of thyroid and autoantibodies in patients with vitiligo in Sanliurfa region

Öz

Background: Vitiligo, a depigmantasyon disorder, affects skin, hair and mucosal membranes. In this study, we aimed to investigate the relationship between the demographic, clinical features of vitiligo patients and autoimmune thyroid diseases in Sanliurfa region.Methods: From 2010 to 2012, we prospectively analyzed 254 vitiligo patients in the Department of Dermatology. The patients were diagnose after clinical and Wood's light examination. Patients' age, gender, age of onset, localization of lesions, initial location of lesions, involvement form of disease, family history of disease were recorded. Patients' and 100 healthy controls' serum free triiodothyronine FT3 , free thyroxine FT4 , thyroid stimulating hormone TSH , antithyroglobulin antibody anti-TG and antithyroid peroxidase antibodies anti-TPO were measured.Results: Two hundred and fifty four [123 male 48.4% and 131 women 51.6% ] of 11,007 patients in the clinic of Dermatology were diagnosed vitiligo. The mean age for women was 22.54±13.8 years, for men 25.32±15.3 years. Mean age of onset of disease for women was 16.58±10.37 and for men 18.45±11.08 years. Compared to control group, there was a statistically significant difference between the levels of serum FT4, TSH, anti-TPO and anti-TG in patients with vitiligo p=0.04, p

Anahtar Kelimeler

• Vitiligo
• demographic factors
• thyroid function tests

Şanlıurfa yöresinde vitiligo hastalarının klinik, demografik özellikleri, tiroid fonksiyonları ve otoantikorları Türkçe

Öz

Amaç: Vitiligo deri, saç ve mukozal membranları etkileyen bir depigmantasyon bozukluğudur. Çalışmamızda Şanlıurfa bölgesindeki vitiligolu hastaların demografik, klinik özellikleri ve otoimmün tiroid hastalıkları ile ilişkisinin irdelenmesi amaçlanmıştır. Materyal ve metod: Bu çalışmada 2010-2012 yılları arasında polikliniğimize başvuran, klinik muayene ve Wood ışığı incelemesi sonucunda vitiligo tanısı almış 254 hasta prospektif olarak değerlendirildi. Olguların yaş, cinsiyet, hastalığın başlangıç yaşı, lezyonların yerleşim yeri, lezyonların başlangıç bölgesi, hastalığın tutulum şekli, hastalığın aile öyküsü kaydedilerek, hastaların ve 100 sağlıklı kontrolün serum serbest triiodotironin sT3 , serbest tiroksin sT4 , tiroid stimüle edici hormon TSH , antitiroglobulin antikor antiTG ve antitiroidperoksidaz antikor anti-TPO düzeyleri ölçüldü. Bulgular: Dermatoloji polikliniğine başvuran 11.007 hastaların 254'ünü %2.31 vitiligo hastaları oluşturmakta idi. İncelenen 254 hastanın, 123'ü erkek %48.4 ve 131'i kadın %51.6 idi. Ortalama yaş kadınlarda 22.54±13.8, erkeklerde 25.32±15.3 yıl olup hastalığın ortalama başlangıç yaşı kadınlarda 16.58±10.37, erkeklerde ise 18.45±11.08 yıl idi. Vitiligolu hastalar ile kontrol grubunun serum sT4, TSH, anti-TPO ve anti-TG düzeyleri arasında istatistiksel olarak anlamlı farklılık saptandı p=0.04, p

Anahtar Kelimeler

• Vitiligo
• demografik faktörler
• tiroid fonksiyon testleri

Kaynakça

1. Onunu AN, Kubeyinje EP. Vitiligo in the Nigerian African: a study of 351 patients in Benin City, Nigeria. Int J Dermatol: 2003; 42(10): 800-2.
2. Bahadır S, Yaylı S: Childhood vitiligo:Epidemiology and etiology. Türkderm: ; 40 (3): 81-6. Jarallah JS, Al-Sheikh OA, El-Shabrawy M, Al- Wakeel MA: Vitiligo:Epidemiology and clinical pattern at King Khalid University Hospital. Ann Saudi Med: 1993; 13(5): 332-4. ,4. George AO: Vitiligo in Ibadan, Nigeria.
3. Incidence, presentation, and problems in management. Int J Dermatol: 1989; 28(7): 385-7.
4. Polat M, Göksügür N, Parlak AH, Tahtacı Y, İbrahimbaş Y, Kılıç B, Şereflican B. Skin disorders in pediatric age groups in Bolu. Turkderm: 2008; : 22-5.
5. Saçar H, Saçar T. Prevalance of dermatosis during childhood. Turkderm: 2010; 44: 132-7.
6. Aksoy F, Evans SE, Karaduman A: Childhood vitiligo:A prospective analysis of 63 patients. Turkiye Klinikleri J Dermatol: 2008; 18: 67-71.
7. Metin A, Güzeloğlu M, Subaşı Ş, Delice İ, Arıca M. Vitiligo disease in Van and surrounding. T Klin J Dermatol: 1999; 9: 22-6.
8. Koranne RV, Sehgal VN, Sachdeva KG: Clinical profile of vitiligo in North India. Indian J Dermatol Venereol Leprol: 1986; 52: 81-2.

9. Handa S, Kaur I. Vitiligo: clinical findings in 1436 patients. J Dermatol: 1999; 26 (10): 653-7.
10. Sarin RC, Kumar AS. A clinical study of vitiligo. Indian J Dermatol Venereol Leprol: 1977; 43: 300
11. Al-Mutairi N, Sharma AK. Profile of Vitiligo in Farwaniya Region in Kuwait. Kuwait Medical Journal: 2006; 38: 128-131.
12. Kovacs SO: Vitiligo. J Am Acad Dermatol: 1998; (5): 647-666.
13. A Kumar, S Neupane, S Parajuli, D Gurung. Profile of Vitiligo in Western Nepal. NJDVL: 2010; : 40-3.
14. Liu JB, Li M, Yang S, Gui JP, Wang HY, Du WH et al. Clinical profiles of vitiligo in China: an analysis of patients. Clin Exp Dermatol: 2005; 30(4): 327
15. Arıcan Ö, Koç K, Ersoy L. Clinical characteristics in 113 Turkish vitiligo patients. Acta Dermatoven APA: 2008; 17(3): 129-132.
16. Akağaç AE, Önalan EE, Yıldırmak ST. Thyroid Functions and Autoantibodies in Vitiligo Patients in Usak Region. Journal of Turkish Clinical Biochemistry: 2011; 9(1): 1-7.
17. Bhalla M, Thami GP. Factors predicting the preference of complementary and alternative systems of medicine in treatment of vitiligo. Indian J Dermatol Venereol Leprol: 2010; 76(6): 705-7.
18. Shah H, Mehta A, Astik B. Clinical and sociodemographic study of vitiligo. Indian J Dermatol Venereol Leprol: 2008; 74(6): 701.
19. Mosher DB, Fitzpatrick TB, Ortanne JB. Disorders of pigmentation, hipomelanoses and hypermelanoses, In: Freedberg IM, Eisen AZ, Fitzpatrick TB, editors. Dermatology in general medicine. 5th ed. New York: McGraw-Hill, 1999: 945.
20. McBurny EL. Vitiligo; clinical picture and pathogenesis. Arch Intern Med: 1979; 139(11): 7.
21. Singh M, Singh G, Kanwar AJ, Belhaj MS. Clinical pattern of vitiligo in Libya. Int J Dermatol: 1985; 24(4): 5.
22. Abel N. Emmanuel P. Vitiligo in the Nigerian African: a study of 351 patients in Benin City, Nigeria International Journal of Dermatology: 2003; 42(10): 2.
23. Nunes DH, Esser LM. Vitiligo epidemiological profile and the association with thyroid disease. An Bras Dermatol: 2011; 86(2): 241-8.
24. Uncu S, Yaylı S, Bahadır S, Okten A, Alpay K. Relevance of autoimmune thyroiditis in children and adolescents with vitiligo. Int J Dermatol: 2011; 50(2): 9.
25. Kasumagic-Halilovic E, Prohic A, Begovic B, Ovcina-Kurtovic N. Association between Vitiligo and Thyroid Autoimmunity. J Thyroid Res: 2011; 2011
26. Nicolaidou E, Antoniou C, Miniati A, Lagogianni E, Matekovits A, Stratigos A et al. Childhood- and later- onset vitiligo have diverse epidemiologic and clinical characteristics. J Am Acad Dermatol: 2012; 66(66): 8.
27. Kroon MW, Joore IC, Wind BS, Leloup MA, Wolkerstorfer A, Luiten RM et al. Low yield of routine screening for thyroid dysfunction in asymptomatic patients with vitiligo. Br J Dermatol: 2012; 166(3): 8.
28. Cho SB, Kim JH, Cho S, Park JM, Park YK, Oh SH. Vitiligo in children and adolescents: association with thyroid dysfunction. J Eur Acad Dermatol Venereol: 2011; 25 (1): 64-7.